A型肉毒杆菌毒素治疗颈部肌张力障碍。

Botulinum toxin A for the treatment of cervical dystonia.

作者信息

Zesiewicz Theresa A, Stamey William, Sullivan Kelly L, Hauser Robert A

机构信息

University of South Florida, Parkinson's disease and Movement Disorders Center, 4 Columbia Drive, Suite 410, Tampa, Florida 33606, USA.

出版信息

Expert Opin Pharmacother. 2004 Sep;5(9):2017-24. doi: 10.1517/14656566.5.9.2017.

DOI:10.1517/14656566.5.9.2017

PMID:15330738

Abstract

Idiopathic cervical dystonia (ICD) is the most common adult-onset focal dystonia. It is characterised by relatively sustained, involuntary contractions of neck muscles. Injections of botulinum toxin (BTX)-A are safe and effective for the treatment of ICD, and have substantially improved its treatment. BTX-A is manufactured by Allergan Pharmaceuticals in the US and Ireland, and is distributed as Botox. In Europe, BTX-A is manufactured and distributed by Ipsen Pharmaceuticals as Dysport. Success rates for BTX-A injections for ICD ranges 64-90%, with 76-93% of injected patients experiencing pain reduction. Side effects are generally mild and include dysphagia and neck weakness.

摘要

特发性颈部肌张力障碍（ICD）是最常见的成人起病型局灶性肌张力障碍。其特征为颈部肌肉相对持续的不自主收缩。注射A型肉毒杆菌毒素（BTX-A）治疗ICD安全有效，并显著改善了其治疗效果。BTX-A由美国和爱尔兰的艾尔建制药公司生产，以保妥适的名称销售。在欧洲，BTX-A由益普生制药公司生产和销售，商品名为Dysport。BTX-A注射治疗ICD的成功率在64%至90%之间，76%至93%的注射患者疼痛减轻。副作用通常较轻，包括吞咽困难和颈部无力。